Anavex: Waiting On Validation As Blarcamesine Shows Some Promise (NASDAQ:AVXL)
· seekingalpha.com
AVXL rated Hold: strong $131.7M cash runway, but blarcamesine’s upside hinges on clearer efficacy and FDA approval.
When it comes to Anavex Life Sciences ( AVXL ), I feel a hold rating would be best at this stage. The balance sheet is clearly a strength for this company, and ...